CGEM Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 6.07%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $2,424,144.13

Cullinan Therapeutics Insider Trading History Chart

Cullinan Therapeutics Share Price & Price History

^$7.89

▲ +0.28 (3.68%)

As of 04/17/2025 05:00 PM ET

Days: 30 | 90 | 365

Cullinan Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/25/2025	Jeffrey Alan Jones	Insider	Sell	4,895	$8.53	$41,754.35	174,164
2/25/2025	Nadim Ahmed	CEO	Sell	12,529	$8.53	$106,872.37	430,621
1/6/2025	Jennifer Michaelson	Insider	Sell	4,000	$12.51	$50,040.00	95,760
12/24/2024	Nadim Ahmed	CEO	Sell	8,400	$11.87	$99,708.00	263,150
12/18/2024	Jennifer Michaelson	Insider	Sell	4,693	$11.41	$53,547.13	99,760
12/12/2024	Jennifer Michaelson	Insider	Sell	3,489	$12.52	$43,682.28	104,453
11/5/2024	Jennifer Michaelson	Insider	Sell	8,000	$15.64	$125,120.00	107,942
9/5/2024	Jennifer Michaelson	Insider	Sell	8,000	$18.09	$144,720.00	115,942
7/5/2024	Jennifer Michaelson	Insider	Sell	8,000	$16.33	$130,640.00	123,942
5/6/2024	Jennifer Michaelson	Insider	Sell	58,000	$28.07	$1,628,060.00	129,582
2/1/2024	Corrine Savill	Insider	Sell	40,000	$16.18	$647,200.00	165,990
1/29/2024	Corrine Savill	Insider	Sell	40,000	$14.09	$563,600.00	165,990
1/22/2024	Corrine Savill	Insider	Sell	18,684	$12.14	$226,823.76	165,990
12/26/2023	Nadim Ahmed	CEO	Sell	4,272	$9.24	$39,473.28	111,550
12/21/2023	Jeffrey Alan Jones	Insider	Sell	1,860	$8.50	$15,810.00	56,191
12/21/2023	Jeffrey Trigilio	CFO	Sell	1,920	$8.50	$16,320.00	83,919
12/18/2023	Jeffrey Alan Jones	Insider	Sell	386	$8.22	$3,172.92	58,051
12/18/2023	Jeffrey Trigilio	CFO	Sell	398	$8.22	$3,271.56	85,839
12/12/2023	Jeffrey Trigilio	CFO	Sell	1,926	$7.81	$15,042.06	86,237
12/12/2023	Jennifer Michaelson	Insider	Sell	1,068	$7.81	$8,341.08	88,965
6/28/2023	Nadim Ahmed	CEO	Sell	759	$11.40	$8,652.60	115,822
6/20/2023	Jeffrey Alan Jones	Insider	Sell	387	$12.94	$5,007.78	58,437
6/20/2023	Jeffrey Trigilio	CFO	Sell	399	$12.94	$5,163.06	85,823
6/12/2023	Jeffrey Trigilio	CFO	Sell	319	$13.11	$4,182.09	86,222
6/12/2023	Jennifer Michaelson	Insider	Sell	176	$13.11	$2,307.36	90,271
6/6/2023	Jennifer Michaelson	Insider	Sell	11,900	$12.31	$146,489.00	90,447
5/23/2023	Nadim Ahmed	CEO	Sell	707	$9.15	$6,469.05	116,581
5/18/2023	Jeffrey Trigilio	CFO	Sell	399	$8.76	$3,495.24	86,541
5/18/2023	Jennifer Michaelson	Insider	Sell	239	$8.76	$2,093.64	90,447
5/12/2023	Jeffrey Trigilio	CFO	Sell	347	$8.78	$3,046.66	86,940
5/12/2023	Jennifer Michaelson	Insider	Sell	193	$8.78	$1,694.54	90,686
4/25/2023	Nadim Ahmed	CEO	Sell	716	$10.59	$7,582.44	117,288
4/18/2023	Jeffrey Alan Jones	Insider	Sell	392	$10.71	$4,198.32	59,218
4/18/2023	Jeffrey Trigilio	CFO	Sell	398	$10.71	$4,262.58	87,287
4/12/2023	Jeffrey Trigilio	CFO	Sell	318	$10.22	$3,249.96	87,685
4/12/2023	Jennifer Michaelson	Insider	Sell	176	$10.22	$1,798.72	91,117
3/23/2023	Nadim Ahmed	CEO	Sell	706	$10.51	$7,420.06	118,004
3/20/2023	Jeffrey Alan Jones	Insider	Sell	390	$11.32	$4,414.80	59,610
3/20/2023	Jeffrey Trigilio	CFO	Sell	399	$11.32	$4,516.68	88,003
11/25/2022	Jennifer Michaelson	Insider	Sell	4,000	$13.30	$53,200.00	53,031
9/27/2022	Jennifer Michaelson	Insider	Sell	4,000	$12.40	$49,600.00	53,031
8/4/2022	Vision Scs F2	Major Shareholder	Sell	25,989	$14.31	$371,902.59	1,255,963
8/2/2022	Vision Scs F2	Major Shareholder	Sell	4,792	$14.10	$67,567.20	1,301,081
7/25/2022	Jennifer Michaelson	Insider	Sell	8,000	$14.51	$116,080.00	53,031
7/18/2022	Corrine Savill	Insider	Sell	5,042	$15.06	$75,932.52	164,573
7/11/2022	Corrine Savill	Insider	Sell	40,000	$13.33	$533,200.00	169,615
6/23/2022	Bioscience I 2017 Ltd F2	Major Shareholder	Sell	29,631	$13.00	$385,203.00	537,392
6/21/2022	Bioscience I 2017 Ltd F2	Major Shareholder	Sell	22,319	$12.77	$285,013.63	616,976
6/6/2022	Nadim Ahmed	CEO	Buy	8,090	$12.40	$100,316.00	8,090
6/1/2022	Bvf Partners L P/Il	Major Shareholder	Buy	751,396	$11.00	$8,265,356.00	4,058,854
5/16/2022	Vision Scs F2	Major Shareholder	Sell	35,158	$11.23	$394,824.34	1,305,873
5/12/2022	Vision Scs F2	Major Shareholder	Sell	264,072	$9.25	$2,442,666.00	1,460,539

See Full Table

SEC Filings (Institutional Ownership Changes) for Cullinan Therapeutics (NASDAQ:CGEM)

86.31% of Cullinan Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Cullinan Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/17/2025	Exchange Traded Concepts LLC	14,107	$0.11M	0.0%	+42.6%	0.024%
4/15/2025	Assenagon Asset Management S.A.	10,062	$76K	0.0%	-92.4%	0.017%
4/8/2025	Rhumbline Advisers	71,338	$0.54M	0.0%	+4.6%	0.122%
4/7/2025	GAMMA Investing LLC	6,995	$53K	0.0%	+1,214.8%	0.012%
3/24/2025	Wellington Management Group LLP	132,976	$1.62M	0.0%	+25.4%	0.227%
3/18/2025	California State Teachers Retirement System	31,251	$0.38M	0.0%	-14.3%	0.053%
2/17/2025	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	91,792	$1.12M	0.0%	+29.4%	0.158%
2/17/2025	Woodline Partners LP	167,315	$2.04M	0.0%	N/A	0.287%
2/17/2025	Squarepoint Ops LLC	19,101	$0.23M	0.0%	-37.9%	0.033%
2/17/2025	Two Sigma Advisers LP	21,900	$0.27M	0.0%	+22.3%	0.038%
2/17/2025	Two Sigma Investments LP	42,205	$0.51M	0.0%	+83.9%	0.072%
2/17/2025	Tema Etfs LLC	28,433	$0.35M	0.1%	N/A	0.049%
2/17/2025	Sphera Funds Management LTD.	205,000	$2.50M	0.5%	+10.3%	0.352%
2/17/2025	Rafferty Asset Management LLC	89,658	$1.09M	0.0%	-21.8%	0.154%
2/17/2025	ProShare Advisors LLC	17,326	$0.21M	0.0%	+31.2%	0.030%
2/17/2025	Patient Square Capital LP	878,897	$10.71M	4.0%	+6.6%	1.509%
2/17/2025	Nuveen Asset Management LLC	227,033	$2.77M	0.0%	-2.8%	0.390%
2/17/2025	OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC	56,095	$0.68M	0.1%	+22.0%	0.096%
2/17/2025	Orbimed Advisors LLC	1,942,555	$23.66M	0.5%	+81.5%	3.336%
2/17/2025	Millennium Management LLC	833,962	$10.16M	0.0%	+5.8%	1.432%
2/17/2025	D. E. Shaw & Co. Inc.	48,932	$0.60M	0.0%	-17.4%	0.084%
2/17/2025	Deutsche Bank AG	580,136	$7.07M	0.0%	+3.4%	0.996%
2/17/2025	Deerfield Management Company L.P. Series C	3,379,399	$41.16M	0.8%	+3.0%	5.804%
2/17/2025	Corton Capital Inc.	11,944	$0.15M	0.1%	N/A	0.021%
2/17/2025	Cubist Systematic Strategies LLC	130,647	$1.59M	0.0%	N/A	0.224%
2/17/2025	Brevan Howard Capital Management LP	14,735	$0.18M	0.0%	N/A	0.025%
2/17/2025	Bank of America Corp DE	155,270	$1.89M	0.0%	-62.1%	0.267%
2/17/2025	BNP Paribas Financial Markets	115,000	$1.40M	0.0%	N/A	0.197%
2/17/2025	Ameriprise Financial Inc.	504,264	$6.14M	0.0%	+20.8%	0.866%
2/17/2025	Algert Global LLC	43,292	$0.53M	0.0%	+8.5%	0.074%
2/14/2025	Boxer Capital Management LLC	907,895	$11.06M	0.9%	N/A	1.559%
2/14/2025	Foresite Capital Management VI LLC	634,558	$7.73M	3.4%	N/A	1.090%
2/14/2025	Northern Trust Corp	500,908	$6.10M	0.0%	+6.4%	0.860%
2/14/2025	Lynx1 Capital Management LP	1,257,795	$15.32M	5.7%	+206.2%	2.160%
2/14/2025	Aquatic Capital Management LLC	6,357	$77K	0.0%	N/A	0.011%
2/14/2025	Virtus ETF Advisers LLC	5,828	$71K	0.0%	+37.8%	0.010%
2/14/2025	Nebula Research & Development LLC	43,702	$0.53M	0.1%	+26.5%	0.075%
2/14/2025	Blue Owl Capital Holdings LP	2,370,972	$28.88M	6.8%	+17.9%	4.072%
2/14/2025	Adage Capital Partners GP L.L.C.	1,030,438	$12.55M	0.0%	-24.0%	1.770%
2/14/2025	Price T Rowe Associates Inc. MD	29,493	$0.36M	0.0%	+15.3%	0.051%
2/14/2025	Rock Springs Capital Management LP	742,114	$9.04M	0.3%	+0.7%	1.274%
2/14/2025	Voss Capital LP	122,361	$1.49M	0.1%	N/A	0.210%
2/14/2025	Tower Research Capital LLC TRC	8,800	$0.11M	0.0%	+411.3%	0.015%
2/14/2025	MetLife Investment Management LLC	32,058	$0.39M	0.0%	+7.4%	0.055%
2/14/2025	Dimensional Fund Advisors LP	1,318,372	$16.06M	0.0%	+28.9%	2.264%
2/13/2025	Marshall Wace LLP	651,693	$7.94M	0.0%	-38.2%	1.119%
2/13/2025	Jump Financial LLC	66,135	$0.81M	0.0%	+130.7%	0.114%
2/13/2025	Walleye Capital LLC	156,497	$1.91M	0.0%	-52.3%	0.269%
2/13/2025	XTX Topco Ltd	43,399	$0.53M	0.0%	N/A	0.075%
2/13/2025	Mariner LLC	34,901	$0.43M	0.0%	+125.3%	0.060%
2/13/2025	Barclays PLC	245,231	$2.99M	0.0%	-1.4%	0.421%
2/13/2025	Optimize Financial Inc	11,755	$0.14M	0.1%	N/A	0.020%
2/13/2025	Kennedy Capital Management LLC	111,049	$1.35M	0.0%	N/A	0.191%
2/13/2025	CenterBook Partners LP	43,987	$0.54M	0.0%	-85.3%	0.076%
2/13/2025	Martingale Asset Management L P	38,545	$0.47M	0.0%	+17.4%	0.066%
2/13/2025	Renaissance Technologies LLC	190,508	$2.32M	0.0%	-32.4%	0.327%
2/13/2025	Legal & General Group Plc	42,808	$0.52M	0.0%	-7.9%	0.074%
2/13/2025	Invesco Ltd.	59,553	$0.73M	0.0%	+2.4%	0.102%
2/13/2025	Federated Hermes Inc.	3,802	$46K	0.0%	+67.0%	0.007%
2/13/2025	Springhill Fund Asset Management HK Co Ltd	276,400	$3.37M	5.5%	N/A	0.475%
2/13/2025	Wells Fargo & Company MN	24,864	$0.30M	0.0%	+47.9%	0.043%
2/12/2025	ExodusPoint Capital Management LP	23,500	$0.29M	0.0%	N/A	0.040%
2/12/2025	Geode Capital Management LLC	1,214,641	$14.80M	0.0%	+0.5%	2.086%
2/12/2025	Franklin Resources Inc.	2,199,709	$26.79M	0.0%	+0.4%	3.778%
2/12/2025	Alliancebernstein L.P.	2,011,525	$24.50M	0.0%	+8.5%	3.454%
2/12/2025	Wellington Management Group LLP	132,976	$1.62M	0.0%	+25.4%	0.228%
2/12/2025	NEOS Investment Management LLC	28,433	$0.35M	0.0%	+10.9%	0.049%
2/12/2025	BIT Capital GmbH	94,344	$1.15M	0.1%	N/A	0.162%
2/12/2025	JPMorgan Chase & Co.	198,214	$2.41M	0.0%	+580.9%	0.340%
2/11/2025	EntryPoint Capital LLC	14,657	$0.18M	0.1%	N/A	0.025%
2/11/2025	Corebridge Financial Inc.	25,719	$0.31M	0.0%	-7.0%	0.044%
2/11/2025	Vanguard Group Inc.	2,936,227	$35.76M	0.0%	-2.1%	5.042%
2/11/2025	KLP Kapitalforvaltning AS	6,800	$83K	0.0%	N/A	0.012%
2/11/2025	American Century Companies Inc.	100,721	$1.23M	0.0%	+11.0%	0.173%
2/11/2025	Intech Investment Management LLC	31,782	$0.39M	0.0%	+81.7%	0.055%
2/10/2025	Swiss National Bank	62,700	$0.76M	0.0%	-14.8%	0.108%
2/10/2025	Connor Clark & Lunn Investment Management Ltd.	20,273	$0.25M	0.0%	N/A	0.035%
2/7/2025	E Fund Management Co. Ltd.	74,843	$0.91M	0.0%	-1.3%	0.129%
2/6/2025	Charles Schwab Investment Management Inc.	430,971	$5.25M	0.0%	+1.7%	0.740%
1/31/2025	New York State Common Retirement Fund	12,918	$0.16M	0.0%	+32.9%	0.022%
1/30/2025	Rhumbline Advisers	68,208	$0.83M	0.0%	+8.5%	0.117%
1/24/2025	China Universal Asset Management Co. Ltd.	12,346	$0.15M	0.0%	+10.7%	0.021%
1/22/2025	Empirical Financial Services LLC d.b.a. Empirical Wealth Management	11,153	$0.14M	0.0%	N/A	0.019%
1/17/2025	SG Americas Securities LLC	23,201	$0.28M	0.0%	+54.1%	0.040%
1/14/2025	Assenagon Asset Management S.A.	133,260	$1.62M	0.0%	-1.3%	0.229%
1/10/2025	Harbor Capital Advisors Inc.	30,747	$0.37M	0.0%	+43.9%	0.053%
12/26/2024	JPMorgan Chase & Co.	29,110	$0.49M	0.0%	+25.1%	0.050%
11/27/2024	Franklin Resources Inc.	2,191,262	$35.56M	0.0%	-10.3%	3.763%
11/16/2024	Geode Capital Management LLC	1,208,421	$20.23M	0.0%	+23.8%	2.075%
11/15/2024	Barclays PLC	248,614	$4.16M	0.0%	+26.0%	0.427%
11/15/2024	Y Intercept Hong Kong Ltd	25,369	$0.43M	0.0%	+40.7%	0.044%
11/15/2024	Wellington Management Group LLP	106,025	$1.78M	0.0%	+47.1%	0.182%
11/15/2024	Sphera Funds Management LTD.	185,871	$3.11M	0.5%	N/A	0.319%
11/15/2024	State Street Corp	2,337,222	$39.13M	0.0%	+20.4%	4.014%
11/15/2024	RTW Investments LP	1,705,960	$28.56M	0.4%	+62.1%	2.930%
11/15/2024	Patient Square Capital LP	824,705	$13.81M	5.1%	N/A	1.416%
11/15/2024	HighVista Strategies LLC	31,893	$0.53M	0.2%	N/A	0.055%
11/15/2024	Holocene Advisors LP	1,533,579	$25.67M	0.1%	+16.5%	2.634%
11/14/2024	PFM Health Sciences LP	182,810	$3.06M	0.2%	-38.2%	0.314%
11/14/2024	Braidwell LP	1,176,173	$19.69M	0.6%	+567.6%	2.020%

Data available starting January 2016

See Full Table

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $7.89

$7.38

$7.99

50 Day Range

MA: $8.36

$7.25

$9.89

52 Week Range

Now: $7.89

$6.85

$30.19

Volume

694,937 shs

Average Volume

648,111 shs

Market Capitalization

$461.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Cullinan Therapeutics?: Cullinan Therapeutics' top insider investors include:
Nadim Ahmed (CEO)
Jeffrey Alan Jones (Insider)
Corrine Savill (Insider)
Jennifer Michaelson (Insider)
Jeffrey Trigilio (CFO)
Learn More about top insider investors at Cullinan Therapeutics.
Who are the major institutional investors of Cullinan Therapeutics?: Cullinan Therapeutics' top institutional investors include:
Rhumbline Advisers — 0.12%
Exchange Traded Concepts LLC — 0.02%
Assenagon Asset Management S.A. — 0.02%
GAMMA Investing LLC — 0.01%
Learn More about top institutional investors of Cullinan Therapeutics stock.
Which institutional investors are selling Cullinan Therapeutics stock?: During the last quarter, CGEM stock was sold by these institutional investors:
Assenagon Asset Management S.A.
In the last year, company insiders that have sold Cullinan Therapeutics company stock include:
Nadim Ahmed (CEO)
Jeffrey Alan Jones (Insider)
Corrine Savill (Insider)
Learn More investors selling Cullinan Therapeutics stock.
Which institutional investors are buying Cullinan Therapeutics stock?: During the last quarter, CGEM stock was bought by institutional investors including:
GAMMA Investing LLC
Exchange Traded Concepts LLC
Rhumbline Advisers